["{\"step_by_step_thinking\": \"The provided documents do not mention vocimagene amiretrorepvec. The first document discusses a therapeutic regimen for refractory or recurrent lymphoma, the second document assesses the ability of quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography to distinguish tumor recurrence from radiation changes after high-dose radiation therapy for malignant gliomas, the third document provides guidance on how to identify and treat patients at risk for recurrent cerebral ischemia, and the fourth document discusses the Bethesda classification for squamous intraepithelial lesions. Therefore, no information is provided about vocimagene amiretrorepvec.\", \"answer_choice\": \"B\"}"]